Genmab A/S (NASDAQ:GMAB – Get Free Report) saw a large increase in short interest in March. As of March 31st, there was short interest totalling 2,400,000 shares, an increase of 17.1% from the March 15th total of 2,050,000 shares. Based on an average daily volume of 626,600 shares, the short-interest ratio is presently 3.8 days. Approximately 0.4% of the company’s shares are sold short.
Analysts Set New Price Targets
Several equities research analysts recently commented on the company. Truist Financial restated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Tuesday, March 26th. Citigroup lowered Genmab A/S from a “neutral” rating to a “sell” rating in a report on Monday, January 22nd. BMO Capital Markets upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and raised their target price for the company from $46.00 to $48.00 in a report on Friday, February 23rd. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Thursday, April 4th. Finally, Morgan Stanley reiterated an “underweight” rating on shares of Genmab A/S in a report on Tuesday, March 26th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $48.50.
Genmab A/S Stock Down 1.6 %
Shares of NASDAQ:GMAB traded down $0.48 during midday trading on Friday, reaching $29.26. 413,219 shares of the company traded hands, compared to its average volume of 390,206. Genmab A/S has a 12 month low of $26.32 and a 12 month high of $42.99. The firm has a market capitalization of $19.33 billion, a price-to-earnings ratio of 30.48, a price-to-earnings-growth ratio of 2.10 and a beta of 0.99. The firm’s fifty day moving average price is $29.27 and its two-hundred day moving average price is $30.48.
Genmab A/S (NASDAQ:GMAB – Get Free Report) last released its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.02. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. The company had revenue of $675.29 million for the quarter, compared to analyst estimates of $678.14 million. Analysts forecast that Genmab A/S will post 1.06 earnings per share for the current year.
Hedge Funds Weigh In On Genmab A/S
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Keybank National Association OH purchased a new position in Genmab A/S during the third quarter worth about $1,154,000. Knights of Columbus Asset Advisors LLC boosted its holdings in shares of Genmab A/S by 16.8% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 5,712 shares of the company’s stock worth $201,000 after purchasing an additional 822 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Genmab A/S by 350.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,845 shares of the company’s stock worth $154,000 after purchasing an additional 3,770 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Genmab A/S by 83.3% in the 3rd quarter. Northern Trust Corp now owns 559,044 shares of the company’s stock worth $19,717,000 after purchasing an additional 254,042 shares in the last quarter. Finally, HBK Sorce Advisory LLC boosted its holdings in shares of Genmab A/S by 4.8% in the 3rd quarter. HBK Sorce Advisory LLC now owns 9,139 shares of the company’s stock worth $322,000 after purchasing an additional 419 shares in the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.